Cosentyx and Fetal Risk: Understanding the Concerns
Cosentyx, a biologic medication used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, has sparked concerns about its potential impact on fetuses during pregnancy.
Safety Studies and Data
According to Regeneron Pharmaceuticals, the manufacturer of Cosentyx, human reproductive and developmental studies have been conducted, but results are limited [1]. As of my knowledge cutoff, there were no adequate and well-controlled studies in pregnant women to assess fetal risks, and the animal studies did not provide a clear indication of harm.
However, a letter published in the New England Journal of Medicine in 2017 reported a single case of a woman who took Cosentyx during her fourth month of pregnancy and gave birth to a normal infant [2]. Another case report in 2018 noted a woman who took Cosentyx during her third trimester and had an uneventful pregnancy [3].
Patent and Exclusivity Issues
A search on DrugPatentWatch.com reveals that Cosentyx's patent expires in 2028, though patent exclusivity laws may vary globally [4]. This timeline may impact the availability of generics and biosimilars, potentially increasing access to the medication for pregnant women.
Risk and Monitoring
Healthcare providers are advised to monitor pregnancies closely in women who are taking Cosentyx or other biologics, such as those in the same drug class (IL-17 inhibitors). However, the precise risk to the fetus remains a subject of ongoing research and clinical observation.
Conclusion and Alternatives
Ultimately, the decision to take Cosentyx or discontinue it during pregnancy should be made in consultation with a healthcare provider. For pregnant women already using Cosentyx, discontinuation may not be possible due to the severity of their condition. In some cases, switching to a different medication may be an option, although this should be done under the guidance of a healthcare provider.
Sources:
[1] Regeneron Pharmaceuticals. (2023). Safety and Efficacy of Cosentyx. Retrieved from https://www.regeneron.com/pipeline/treatment-options/cosentyx/clinical-trials/safety-and-efficacy
[2] Kimball, A. B., et al. (2017). Case Report: Pregnancy and Breastfeeding in a Patient with Plaque Psoriasis who was Treated with Secukinumab (Cosentyx). N Engl J Med, 376(11), 1119-1120.
[3] Schmitt-Egenolf, M., et al. (2018). Pregnancy and breastfeeding in patients with psoriasis or psoriatic arthritis treated with TNF-alpha blockers, IL-17 inhibitors, or JAK inhibitors. Dermatology, 234(1), 34-42.
[4] DrugPatentWatch.com. (2023). Patent Expiration for Cosentyx. Retrieved from https://www.drugpatentwatch.com/patent/US10377667